In the context of HNSCC, C-MYC has been demonstrated to engage directly with the NFE2L2 promoter, leading to the upregulation of Nrf2 expression and subsequently facilitating the malignant characteristics of cancer by altering nucleotide biosynthesis pathways 78. This evidence concerns the gene NFE2L2 and cancer.